SCNI Stock Overview
A development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Scinai Immunotherapeutics Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.02 |
| 52 Week High | US$8.92 |
| 52 Week Low | US$2.23 |
| Beta | 2.46 |
| 11 Month Change | -16.57% |
| 3 Month Change | -25.43% |
| 1 Year Change | -50.41% |
| 33 Year Change | -98.36% |
| 5 Year Change | -99.47% |
| Change since IPO | -99.24% |
Recent News & Updates
Recent updates
Here's Why BiondVax Pharmaceuticals (NASDAQ:BVXV) Can Afford Some Debt
Nov 10
Bionvax Pharmaceuticals GAAP EPS of -NIS0.02
Aug 25BiondVax, European Investment Bank agree on new terms to co's outstanding €24M loan
Aug 10We Think BiondVax Pharmaceuticals (NASDAQ:BVXV) Has A Fair Chunk Of Debt
Mar 31BiondVax Pharmaceuticals under pressure on pricing $12.1M ADSs follow-on offering
Jan 29Shareholder Returns
| SCNI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.3% | -6.5% | -1.0% |
| 1Y | -50.4% | 14.6% | 30.3% |
Return vs Industry: SCNI underperformed the US Biotechs industry which returned 14.6% over the past year.
Return vs Market: SCNI underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| SCNI volatility | |
|---|---|
| SCNI Average Weekly Movement | 15.0% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SCNI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SCNI's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 31 | Amir Reichman | www.scinai.com |
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd.
Scinai Immunotherapeutics Ltd. Fundamentals Summary
| SCNI fundamental statistics | |
|---|---|
| Market cap | US$2.46m |
| Earnings (TTM) | -US$3.70m |
| Revenue (TTM) | US$284.00k |
8.9x
P/S Ratio-0.7x
P/E RatioIs SCNI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SCNI income statement (TTM) | |
|---|---|
| Revenue | US$284.00k |
| Cost of Revenue | US$448.00k |
| Gross Profit | -US$164.00k |
| Other Expenses | US$3.54m |
| Earnings | -US$3.70m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.42 |
| Gross Margin | -57.75% |
| Net Profit Margin | -1,304.23% |
| Debt/Equity Ratio | -272.1% |
How did SCNI perform over the long term?
See historical performance and comparison